A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Pridopidine (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Acronyms Open PRIDE-HD
- Sponsors Teva Branded Pharmaceutical Products R&D
- 23 Nov 2017 This trial has been discontinued in Germany.
- 17 Nov 2017 This trial has been discontinued in Austria.
- 02 Nov 2017 Planned End Date changed from 20 Oct 2022 to 27 Apr 2023.